ITGB2 and myeloid sarcoma: To investigate the impact of myeloid-specific deletion of Mac-1 on the pathogenesis of MS, we evaluated the development of EAE in myeMac-1KO mice and their wild-type (WT) littermate controls by immunizing them with MOG35-55/Freund’s complete adjuvant (FCA) and monitoring the clinical scores for 30 days.